Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Propentofylline

Introduction

Overview

Overview

Propentofylline (HWA 285) is a xanthine derivative with purported neuroprotective effects.

Pharmacology

Pharmacology

It is a phosphodiesterase inhibitor.[1]

It also acts as an adenosine reuptake inhibitor.[1][2][3]

Uses

Uses

It was studied as a possible treatment for Alzheimer’s disease and multi-infarct dementia.[4][5]

Propentofylline has also been studied, to a lesser extent, as a possible adjunct in the treatment of ischemic stroke, due to its vasodilating properties.[6][7]

Propentofylline is in use in veterinary medicine as a geriatric preparation for old dogs.

See also

See also

References

References

  1. ↑ 1.0 1.1 Frampton M, Harvey RJ, Kirchner V (2003). Frampton, Maria A, ed. “Propentofylline for dementia”. Cochrane Database Syst Rev (2): CD002853. doi:10.1002/14651858.CD002853. PMID 12804440.
  2. ↑ Salimi S; Fotouhi A; Ghoreishi A; et al. (April 2008). “A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia”. Prog. Neuropsychopharmacol. Biol. Psychiatry. 32 (3): 726–732. doi:10.1016/j.pnpbp.2007.11.021. PMID 18096287. Unknown parameter |author-separator= ignored (help)
  3. ↑ Numagami Y, Marro PJ, Mishra OP, Delivoria-Papadopoulos M (June 1998). “Effect of propentofylline on free radical generation during cerebral hypoxia in the newborn piglet”. Neuroscience. 84 (4): 1127–1133. doi:10.1016/S0306-4522(97)00542-3. PMID 9578400.
  4. ↑ Frampton M, Harvey RJ, Kirchner V (2003). Frampton, Maria A, ed. “Propentofylline for dementia”. Cochrane database of systematic reviews (Online) (2): CD002853. doi:10.1002/14651858.CD002853. PMID 12804440.
  5. ↑ Kittner B, Rössner M, Rother M (1997). “Clinical trials in dementia with propentofylline”. Ann. N. Y. Acad. Sci. 826: 307–316. doi:10.1111/j.1749-6632.1997.tb48481.x. PMID 9329701.
  6. ↑ Bath PM, Bath-Hextall FJ (2004). Bath, Philip MW, ed. “Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke”. Cochrane database of systematic reviews (Online) (3): CD000162. doi:10.1002/14651858.CD000162.pub2. PMID 15266424.
  7. ↑ Huber M, Kittner B, Hojer C, Fink GR, Neveling M, Heiss WD (1993). “Effect of propentofylline on regional cerebral glucose metabolism in acute ischemic stroke”. J. Cereb. Blood Flow Metab. 13 (3): 526–30. doi:10.1038/jcbfm.1993.68. PMID 8478410.

Template:Phosphodiesterase inhibitors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]